ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VCYT Veracyte Inc

19.31
-0.17 (-0.87%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Veracyte Inc NASDAQ:VCYT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.17 -0.87% 19.31 18.99 19.65 19.77 19.16 19.55 629,746 00:18:02

Veracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference

15/11/2017 3:00pm

Business Wire


Veracyte (NASDAQ:VCYT)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Veracyte Charts.

Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Piper Jaffray 29th Annual Healthcare Conference on Tuesday, November 28, 2017 at 9:30 a.m. Eastern Time in New York, NY.

The live webcast from the Piper Jaffray presentation and subsequent replay may be accessed by visiting Veracyte's website at http://investor.veracyte.com. The replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for 90 days following the presentation.

About Veracyte

Veracyte (NASDAQ: VCYT) is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte and the Veracyte logo are trademarks of Veracyte, Inc.

Veracyte, Inc.Media:Tracy Morris, 650-380-4413tracy.morris@veracyte.comorInvestors:Jackie Cossmon, 650-243-6371jackie@veracyte.com

1 Year Veracyte Chart

1 Year Veracyte Chart

1 Month Veracyte Chart

1 Month Veracyte Chart

Your Recent History

Delayed Upgrade Clock